Damora Therapeutics (DMRA) Change in Account Payables (2019 - 2026)
Damora Therapeutics (DMRA) posted Change in Account Payables of $375000.0 for Q1 2026, up 507.61% on a QoQ basis from -$92000.0 in Q4 2025, and up 1730.43% year-over-year from $20486.9 in Q1 2025.
Damora Therapeutics (DMRA) Change in Account Payables (2019 - 2026) Analysis & Trends
Damora Therapeutics' Change in Account Payables history runs 8 years deep, the most recent figure standing at $375000.0 for Q1 2026.
- Quarterly Change in Account Payables rose 1730.43% year-over-year to $375000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $449000.0 (up 134.25% YoY) and the FY2025 annual result came in at $51000.0, up 103.85% from the prior year.
- Change in Account Payables was $375000.0 for Q1 2026 at Damora Therapeutics, up from -$92000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $2.0 million in Q2 2023 and bottomed at -$2.8 million in Q4 2023.
- A 5-year average of -$42823.5 and a median of -$92000.0 in 2025 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2022 — Change in Account Payables slumped 329.87% — and 2026, when it soared 1730.43%.
- Damora Therapeutics' Change in Account Payables stood at $1.4 million in 2022, then slumped by 292.31% to -$2.8 million in 2023, then soared by 95.46% to -$126000.0 in 2024, then climbed by 26.98% to -$92000.0 in 2025, then jumped by 507.61% to $375000.0 in 2026.
- Business Quant data shows DMRA's Change in Account Payables at $375000.0 in Q1 2026, -$92000.0 in Q4 2025, and -$236000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Damora Therapeutics | 1.00 Bn | 798.11 Mn | - | 375,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 375,000.00 |
| Mar 31, 2026 | 375,000.00 |
| Dec 31, 2025 | -92,000.00 |
| Dec 31, 2025 | -92,000.00 |
| Sep 30, 2025 | -236,000.00 |
| Sep 30, 2025 | -236,000.00 |
| Jun 30, 2025 | 402,000.00 |
| Jun 30, 2025 | 402,000.00 |
| Mar 31, 2025 | -23,000.00 |
| Mar 31, 2025 | -23,000.00 |
| Dec 31, 2024 | -126,000.00 |
| Dec 31, 2024 | -126,000.00 |
| Sep 30, 2024 | -221,000.00 |
| Sep 30, 2024 | -221,000.00 |
| Jun 30, 2024 | -941,000.00 |
| Jun 30, 2024 | -941,000.00 |
| Mar 31, 2024 | -37,000.00 |
| Mar 31, 2024 | -37,000.00 |
| Dec 31, 2023 | -2.78 Mn |
| Dec 31, 2023 | -2.78 Mn |